DTaP-Hib vaccine explained

DTaP-Hib vaccine is a combination vaccine whose generic name is diphtheria and tetanus toxoids and acellular pertussis adsorbed with Haemophilus B conjugate vaccine, sometimes abbreviated to DTaP-Hib.[1] It protects against the infectious diseases diphtheria, tetanus, pertussis, and Haemophilus influenzae type B.[2]

A branded formulation was marketed in the US as TriHIBit by Sanofi Pasteur, and administered by using the Sanofi DTaP vaccine Tripedia to reconstitute the Sanofi Hib vaccine ActHIB.[2] [3] [4] TriHIBit and Tripedia were discontinued in 2011.[5]

See also

Notes and References

  1. Web site: Trihibit (diphtheria toxoid / haemophilus b conjugate (prp-t) vaccine / pertussis, acellular / tetanus toxoid) Disease Interactions. 15 July 2018. Drugs.com.
  2. Web site: Notice to Readers FDA Approval of a Haemophilus b Conjugate Vaccine Combined by Reconstitution with an Acellular Pertussis Vaccine. Centers for Disease Control and Prevention. 15 July 2018. Morbidity and Mortality Weekly Report. 45. 45. 993–995. 15 November 1996.
  3. Web site: https://wayback.archive-it.org/7993/20170112211659/http:/www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM101580.pdf. 12 January 2017. Tripedia package insert. dead. US Food and Drug Administration. 15 July 2018.
  4. Web site: ActHIB package insert. US Food and Drug Administration. 15 July 2018.
  5. Web site: Selected Discontinued U.S. Vaccines. Centers for Disease Control and Prevention. 15 July 2018.

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "DTaP-Hib vaccine".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.